[Modern Healthcare] Excessive drug costs could invite price caps: AHIP’s Ignagni

By Paul Demko May 21, 2014   The steep cost of Sovaldi—Gilead Sciences’ $1,000-per-pill treatment for hepatitis C—is prompting wide-ranging discussions about the cost of drugs […]

Read more

[The Hill] Insurance lobby: Let’s beat government to drug cost reform

By Ferdous Al-Faruque May 21, 2014   The top health insurance lobbyist in the country says stakeholders are at a “crossroad” on addressing the growing cost of […]

Read more

[Reuters] U.S. health insurers say Gilead hepatitis C drug too costly

By Bill Berkrot May 21, 2014   The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing […]

Read more

[Inside Health Policy] Spurred By Sovaldi’s Price, Drug Makers & Plans Consider Mortgaging Pricey Drugs

By John Wilkerson May 21, 2014   Spurred by the prospect of Sovaldi’s high cost, some policy wonks are talking about letting plans and state Medicaid […]

Read more